Literature DB >> 4790698

Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma.

M Moore, D E Williams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4790698     DOI: 10.1002/ijc.2910110213

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  15 in total

1.  Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate.

Authors:  R Bhatti; P Ray; N Bell
Journal:  Urol Res       Date:  1991

2.  Rescue of anti-influenza A virus cytotoxic T-lymphocyte responses in chemotherapy-suppressed mice.

Authors:  V J Merluzzi; K Welte; R H Mertelsmann; L Souza; T Boone; K Last-Barney
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

3.  Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.

Authors:  Y Umeda; A Sakamoto; J Nakamura; H Ishitsuka; Y Yagi
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.

Authors:  E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Mechanism of the antitumor activity of 5,5'-bis(2'-tetrahydropyranyl) secalonic acid D against Meth-A.

Authors:  M Shimizu; M Nakamura; T Kataoka; T Iwaguchi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge.

Authors:  D Vidović; M Marusić; F Culo
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

9.  The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.

Authors:  T Palomares; P Bilbao; A Alonso-Varona; E Barberá-Guillem
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

10.  Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels.

Authors:  R Evans
Journal:  Am J Pathol       Date:  1980-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.